A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter Y. Yin
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors Y. Yin1, S. Tang2, C. Shen3, B. Zhang4
  • 1West China Hospital, Chengdu City, China, /
  • 2Sichuan University, West China Hospital, Chengdu City, China, /
  • 3West China Hospital, Chengdu, China, /
  • 4West China Hospital, Sichuan University, Chengdu, China, /

Abstract

To investigate the efficiency and safety of reducing imatinib dose in patients with gastrointestinal stromal tumor who can not tolerate standard dose of imatinib (400mg/d).